DexCom, Inc. (DXCM)
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DexCom Stock Falls Despite Q4 Earnings Beat, G7 Rollout Drives Growth
DXCM beats Q4 EPS estimates, posts 13% revenue growth and reiterates 2026 guidance as G7 15 Day rollout and margin gains drive momentum.
DexCom, Inc. (DXCM) Q4 2025 Earnings Call Transcript
DexCom, Inc. (DXCM) Q4 2025 Earnings Call Transcript
DexCom (DXCM) Q4 Earnings and Revenues Top Estimates
DexCom (DXCM) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.45 per share a year ago.
Will DXCM Deliver Q4 Earnings Beat on G7 Stabilization, Volume Growth?
DexCom heads into Q4 earnings with easing G7 issues, improving supply chains and rebounding U.S. new customer starts lifting revenue outlook.
DXCM Upgrades Stelo With AI-Powered Smart Meal Logging Features
Dexcom plans a nationwide AI upgrade to Stelo, adding a million-plus food database and smarter insights to improve glucose understanding and wellness goals.
DexCom (DXCM) Reports Next Week: Wall Street Expects Earnings Growth
DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DexCom (DXCM) is a Top-Ranked Growth Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Here's Why DexCom (DXCM) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DexCom Stock Declines Following Strong Preliminary Q4 Results
DXCM posts strong preliminary Q4 and full-year 2025 revenue growth, beating estimates, though shares slip after the announcement.
Here's Why You Should Hold DexCom Stock in Your Portfolio for Now
DXCM looks poised for growth as CGM demand expands, G7 and One+ adoption accelerates, and strong Q4 results support a hold stance.
